News >

Progress Continues in EGFR+ NSCLC Paradigm

Caroline Seymour
Published: Monday, Jul 16, 2018

Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH
Recent progress in the treatment paradigm for EGFR-mutant non–small cell lung cancer (NSCLC) includes the FDA’s frontline approval of osimertinib (Tagrisso) and priority review designation for dacomitinib, both of which have demonstrated longer progression-free survival (PFS) and overall survival (OS) outcomes versus standard therapy, said Charu Aggarwal, MD.

-mutant lung cancer.

OncLive: Can you discuss recent advances in EGFR-mutant NSCLC?

Aggarwal: I spoke about the preferential use of osimertinib (Tagrisso), which is our third-generation tyrosine kinase inhibitor (TKI) in the first-line setting. That offers patients a tremendous opportunity to live longer, as well as avoid some of the other side effects with first- or second-generation TKIs.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x